Cxbladder is a non-invasive genomic urine test optimised for the detection and management of bladder cancer

  • Accurate rule out, reducing the need for further invasive procedures
  • Resolve atypical cytology and equivocal cystoscopy
  • Improve overall detection accuracy

Cxbladder works at a molecular level. The test combines clinical risk factor markers with genetic information, measuring five biomarker genes to detect the presence or absence of bladder cancer.

  • Reliable: Cxbladder utilises high sensitivity and negative predictive value to either help rule out the disease or complement other diagnostic procedures and tests to improve overall detection accuracy.
  • Clinically proven: Proven performance in 12 peer-reviewed publications for rule out, primary detection, and surveillance. Cxbladder is used by over 1,800 urologists in more than 40,000 patients across the US, while 65% of the New Zealand population now have access to the test via public healthcare.
  • Easy-to-use: Cxbladder’s unique urine sample collection system is discrete, non-invasive and easy-to-use, taking only minutes.
  • Quick: Upon receiving a urine sample, our certified NZ laboratory will provide actionable results in 5 days

Contact Us to Request More Information

A Suite of Tests Optimised to Primary Detection and Surveillance

Cxbladder is a suite of three tests each optimised for a specific point along the patient journey.

cxbladder family of products

Cxbladder Triage

Designed for patients presenting with haematuria. Cxbladder Triage analyses the presence of five biomarker genes alongside information on known bladder cancer risk factors like age, gender and smoking history to rule out patients with a low risk of having the disease.

Cxbladder Triage provides accurate results and reassurance that can reduce the need for further invasive procedures.

Cxbladder Detect

In cases where a patient is symptomatic and bladder cancer looks likely, Cxbladder Detect can help confirm your diagnosis.

By detecting and quantifying signs of cancer at the molecular level, Cxbladder Detect outperforms other urine-based tests, making it an ideal choice for bladder cancer testing when patients present with significant symptoms. Cxbladder Detect can be used as an adjunct to cystoscopy or as a substitute for other radiological tests to improve overall detection accuracy. The test can also provide certainty when other procedures and tests are inconclusive. Cxbladder Detect is proven to adjudicate atypical cytology and equivocal cystoscopy. 

Cxbladder Monitor

Developed specifically for patients undergoing surveillance for recurrent bladder cancer. The test combines clinical information linked to previous bladder cancer with measured biomarker genes to help rule out the presence of a recurrent tumour, or to indicate that further clinical investigation is required.

Cxbladder Monitor can provide accurate results with a single urine sample, and test is often used as a non-invasive monitoring alternative to reduce the need for frequent cystoscopies.
Request More Info on Triage, Detect or Monitor

The Difference in Cancer Detection

Cxbladder is a reliable test for bladder cancer that can help you make informed treatment and care decisions.

Most symptomatic or surveillance patients do not have bladder cancer. Cxbladder enables the accurate rule out of patients with haematuria and those being monitored for recurrence, reducing the burden of cystoscopy and sparing patients anxiety and discomfort. The test also solves a diagnostic dilemma, accurately resolving atypical cytology and equivocal cystoscopy in the evaluation of patients presenting with haematuria or being monitored for recurrence.
Contact Us to Request More Information

Last Updated: 03 May 2021 10:17 am

  • References

    Cxbladder was developed by a company whose passion and focus is cancer diagnostics and prognostics to improve patient outcomes. See our full list of clinical publications.

    Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).

Diagnosing bladder cancer

Drs Sia Daneshmand and Joseph DiTrolio discuss the guidelines, issues and technologies for diagnosing UC in patients presenting with hematuria in primary care.

Diagnosing bladder cancer
Diagnosing bladder cancer